Recent investigations demonstrated that amplification of ERBB2 (also called HER2) oncogenic form was found in esophageal adenocarcinoma progression, leading to a worse outcome for EAC [39]. This evidence concerns the gene ERBB2 and esophageal adenocarcinoma.